Seagen Founder Clay Siegall Returns as CEO of Purdue Spinout After Pfizer's $43B Acquisition Deal

Clay Siegall, co-founder and former CEO of Seagen, which is set to be acquired by Pfizer for $43 billion, has returned to biotech as CEO of Purdue University spinout Morphimmune. Despite stepping down amid a personal incident, Siegall remains proud of Seagen’s impact on cancer treatments, particularly in advancing antibody-drug conjugates.

More: GeekWire

No comments yet.